Tiamutin has proven synergistic activity against important respiratory pathogens such as
M. hyopneumoniae, Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis and Bordetella bronchiseptica, when used in combination with chlortetracycline (CTC). [?], [?], [?] (See following table).
| UK |
Miller and Stipkovits(1991), Burch and others(1986), Jones (1984) |
| In vitro synergism between Tiamutin® (tiamulin) and CTC (MICs in µg/ml) against respiratory pathogens |
| |
|
|
Combined
Tiamulin/CTC
|
Synergy factor
(X)
|
| Organism (strains tested) |
Tiamulin
|
Chlortet
(CTC)
|
Tia
|
CTC
|
Tia
|
CTC
|
| M. hyopneumoniae |
0.13
|
2.0
|
0.016
|
1.0
|
8x
|
2x
|
| A. pleuropneumoniae (9) |
3.9
|
0.9
|
1.1
|
0.22
|
3.6x
|
4x
|
| P. multocida (8) |
15.8
|
12.8
|
2.9
|
3.2
|
5.4x
|
4x
|
| H. parasuis (1) |
0.9
|
1.9
|
0.45
|
0.45
|
2x
|
4.2x
|
| B. bronchiseptica (1) |
250
|
0.45
|
0.45
|
0.22
|
555x
|
2x
|
|
| M. hyopneumoniae synergy |
A. pleuropneumoniae synergy |
 |
 |
Tia/CTC combination premix provides truly comprehensive broad spectrum systemic activity, [?], [?], [?], [?] which is particularly valuable in complex clinical situations of mixed microbial origin, e.g. porcine respiratory disease complex (PRDC) and post-weaning multi-systemic wasting syndrome (PMWS) or PRRSV-infections.
A similar synergism exists with doxycycline [?], [?] and oxytetracycline (OTC). [?] (See following tables)
| HUNGARY |
Fodor, L. and others (2004) Stipkovits, L. and others (2004) |
| In vitro synergism between Tiamutin® (tiamulin) and doxycycline against Mycoplasma spp. and respiratory bacterial pathogens (MICs in µg/ml)* |
| |
|
|
Combined
Tiamulin/Doxy
|
Synergy factor
(X)
|
| Organism |
Tiamulin
|
Doxy
|
Tia
|
CTC
|
Tia
|
Doxy
|
| M. hyopneumoniae |
0.219
|
5.169
|
0.094
|
0.659
|
2.3x
|
7.8x
|
| M. hyorhinis |
0.219
|
0.933
|
0.116
|
0.094
|
1.9x
|
9.9x
|
| M. hyosynoviae |
0.120
|
1.101
|
0.044
|
0.116
|
2.7x
|
9.5x
|
| A. pleuropneumoniae |
2.297
|
0.435
|
1.071
|
0.088
|
2.1x
|
4.9x
|
| Past. multocida |
2.297
|
0.125
|
0.870
|
0.016
|
2.6x
|
7.8x
|
| Strep. suis |
0.094
|
0.189
|
0.044
|
0.025
|
2.1x
|
7.6x
|
| B. bronchiseptica |
16.0
|
0.088
|
5.656
|
0.017
|
2.8x
|
5.2x
|
|
| KOREA |
Koh, H.B. and others (1994) |
| MIC’s of Tiamutin® (tiamulin) and OTC against 7 field isolates of M. hyo |
|
MIC (µg/ml)
|
| |
|
|
Combined
Tiamulin/OTC
|
Synergy factor
(X)
|
| M. hyo Isolate No. |
Tiamulin
|
(OTC)
|
Tia
|
OTC
|
Tia
|
OTC
|
| 1017 |
0.78
|
0.78
|
0.23
|
0.12
|
3.4x
|
6.5x
|
| 1034 |
0.78
|
3.20
|
0.47
|
0.23
|
1.66x
|
13.9x
|
| 2021 |
0.39
|
0.78
|
0.23
|
0.12
|
1.70x
|
6.5x
|
| 2022 |
0.39
|
0.78
|
0.47
|
0.23
|
anta
|
gonism
|
| 2031 |
0.39
|
0.78
|
0.23
|
0.12
|
1.70x
|
6.5x
|
| 2039 |
0.39
|
3.20
|
0.23
|
0.12
|
1.70x
|
26.7x
|
| 2047 |
0.39
|
0.78
|
0.23
|
0.12
|
1.70x
|
6.5x
|
|
Strategic ‘pulsed’ dosing with tiamulin/CTC premix medication can significantly improve growth performance, mortality rates and profitability whilst permitting the stimulation of active immunity against mycoplasmal pneumonia. [?] (See here)
| 
